STOCK TITAN

Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

On September 23, 2021, Annexon (Nasdaq: ANNX), a biopharmaceutical company, announced that its CEO, Douglas Love, will speak at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 12:40 p.m. ET. The event will be available via a live webcast on Annexon's Investors page and will be archived for 30 days post-presentation. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with a pipeline that includes innovative products like ANX005, ANX007, and ANX009.

Loading...
Loading translation...
Argus Session date unavailable
+3.36% session move Open Argus
Details

News Market Reaction – ANNX

The recorded move for ANNX in the trading session of this news was +3.36%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that Douglas Love, Esq., President & Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 12:40 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Contacts:

Investors:
Jennifer Lew
Chief Financial Officer, Annexon Biosciences
jlew@annexonbio.com

Media:
Miriam Mason
Annexon Biosciences
mmason@annexonbio.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Annexon CEO Douglas Love participate in the Cantor Virtual Global Healthcare Conference?

Douglas Love will participate in the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 12:40 p.m. ET.

How can I watch the Annexon presentation at the conference?

You can watch the Annexon presentation live on the Investors page of their website, and it will be archived for 30 days after the event.

What is Annexon developing as part of their pipeline?

Annexon is developing a new class of complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders, including product candidates like ANX005, ANX007, and ANX009.

What types of disorders does Annexon's research focus on?

Annexon's research focuses on classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.

Keep reading